|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SHC2 |
Gene summary for SHC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SHC2 | Gene ID | 25759 |
| Gene name | SHC adaptor protein 2 | |
| Gene Alias | SCK | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P98077 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25759 | SHC2 | HCC1_Meng | Human | Liver | HCC | 1.57e-25 | -2.04e-02 | 0.0246 |
| 25759 | SHC2 | HCC2_Meng | Human | Liver | HCC | 2.91e-13 | 1.53e-01 | 0.0107 |
| 25759 | SHC2 | HCC2 | Human | Liver | HCC | 8.40e-11 | 3.76e+00 | 0.5341 |
| 25759 | SHC2 | S015 | Human | Liver | HCC | 1.64e-02 | 2.83e-01 | 0.2375 |
| 25759 | SHC2 | S027 | Human | Liver | HCC | 5.97e-10 | 9.47e-01 | 0.2446 |
| 25759 | SHC2 | S028 | Human | Liver | HCC | 2.94e-19 | 8.99e-01 | 0.2503 |
| 25759 | SHC2 | S029 | Human | Liver | HCC | 7.77e-10 | 5.44e-01 | 0.2581 |
| 25759 | SHC2 | male-WTA | Human | Thyroid | PTC | 1.22e-18 | 2.16e-01 | 0.1037 |
| 25759 | SHC2 | PTC04 | Human | Thyroid | PTC | 1.98e-05 | 2.23e-01 | 0.1927 |
| 25759 | SHC2 | PTC05 | Human | Thyroid | PTC | 1.72e-06 | 3.20e-01 | 0.2065 |
| 25759 | SHC2 | PTC06 | Human | Thyroid | PTC | 9.06e-03 | 6.02e-02 | 0.2057 |
| 25759 | SHC2 | PTC07 | Human | Thyroid | PTC | 7.83e-16 | 2.67e-01 | 0.2044 |
| 25759 | SHC2 | ATC13 | Human | Thyroid | ATC | 2.13e-55 | 1.00e+00 | 0.34 |
| 25759 | SHC2 | ATC3 | Human | Thyroid | ATC | 2.41e-02 | 1.80e-01 | 0.338 |
| 25759 | SHC2 | ATC5 | Human | Thyroid | ATC | 3.18e-56 | 1.07e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
| GO:0032535 | Colorectum | AD | regulation of cellular component size | 142/3918 | 383/18723 | 1.74e-13 | 3.41e-11 | 142 |
| GO:1902903 | Colorectum | AD | regulation of supramolecular fiber organization | 139/3918 | 383/18723 | 2.01e-12 | 3.19e-10 | 139 |
| GO:0032970 | Colorectum | AD | regulation of actin filament-based process | 142/3918 | 397/18723 | 4.05e-12 | 5.90e-10 | 142 |
| GO:0110053 | Colorectum | AD | regulation of actin filament organization | 108/3918 | 278/18723 | 5.02e-12 | 6.98e-10 | 108 |
| GO:0008154 | Colorectum | AD | actin polymerization or depolymerization | 90/3918 | 218/18723 | 6.14e-12 | 8.23e-10 | 90 |
| GO:0032271 | Colorectum | AD | regulation of protein polymerization | 94/3918 | 233/18723 | 1.01e-11 | 1.29e-09 | 94 |
| GO:0030041 | Colorectum | AD | actin filament polymerization | 81/3918 | 191/18723 | 1.35e-11 | 1.69e-09 | 81 |
| GO:0051258 | Colorectum | AD | protein polymerization | 112/3918 | 297/18723 | 1.85e-11 | 2.27e-09 | 112 |
| GO:0043254 | Colorectum | AD | regulation of protein-containing complex assembly | 148/3918 | 428/18723 | 2.64e-11 | 3.18e-09 | 148 |
| GO:0008064 | Colorectum | AD | regulation of actin polymerization or depolymerization | 79/3918 | 188/18723 | 4.17e-11 | 4.74e-09 | 79 |
| GO:0030833 | Colorectum | AD | regulation of actin filament polymerization | 74/3918 | 172/18723 | 4.50e-11 | 5.03e-09 | 74 |
| GO:0030832 | Colorectum | AD | regulation of actin filament length | 79/3918 | 189/18723 | 5.71e-11 | 6.27e-09 | 79 |
| GO:1902905 | Colorectum | AD | positive regulation of supramolecular fiber organization | 85/3918 | 209/18723 | 5.95e-11 | 6.33e-09 | 85 |
| GO:0032956 | Colorectum | AD | regulation of actin cytoskeleton organization | 127/3918 | 358/18723 | 1.03e-10 | 1.04e-08 | 127 |
| GO:0051495 | Colorectum | AD | positive regulation of cytoskeleton organization | 89/3918 | 226/18723 | 1.61e-10 | 1.56e-08 | 89 |
| GO:0016197 | Colorectum | AD | endosomal transport | 90/3918 | 230/18723 | 1.88e-10 | 1.73e-08 | 90 |
| GO:0032273 | Colorectum | AD | positive regulation of protein polymerization | 62/3918 | 138/18723 | 1.94e-10 | 1.76e-08 | 62 |
| GO:0031334 | Colorectum | AD | positive regulation of protein-containing complex assembly | 91/3918 | 237/18723 | 4.78e-10 | 3.99e-08 | 91 |
| GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0491041 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
| hsa0522021 | Liver | HCC | Chronic myeloid leukemia | 55/4020 | 76/8465 | 8.67e-06 | 6.91e-05 | 3.84e-05 | 55 |
| hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| hsa0451041 | Liver | HCC | Focal adhesion | 125/4020 | 203/8465 | 3.12e-05 | 1.88e-04 | 1.04e-04 | 125 |
| hsa0510022 | Liver | HCC | Bacterial invasion of epithelial cells | 51/4020 | 77/8465 | 6.67e-04 | 2.72e-03 | 1.52e-03 | 51 |
| hsa0472210 | Liver | HCC | Neurotrophin signaling pathway | 74/4020 | 119/8465 | 8.27e-04 | 3.26e-03 | 1.81e-03 | 74 |
| hsa040128 | Liver | HCC | ErbB signaling pathway | 54/4020 | 85/8465 | 2.02e-03 | 7.07e-03 | 3.93e-03 | 54 |
| hsa052142 | Liver | HCC | Glioma | 47/4020 | 75/8465 | 5.67e-03 | 1.62e-02 | 9.02e-03 | 47 |
| hsa049262 | Liver | HCC | Relaxin signaling pathway | 75/4020 | 129/8465 | 9.33e-03 | 2.46e-02 | 1.37e-02 | 75 |
| hsa0152121 | Liver | HCC | EGFR tyrosine kinase inhibitor resistance | 48/4020 | 79/8465 | 1.19e-02 | 2.99e-02 | 1.66e-02 | 48 |
| hsa01522 | Liver | HCC | Endocrine resistance | 58/4020 | 98/8465 | 1.28e-02 | 3.19e-02 | 1.78e-02 | 58 |
| hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| hsa0491051 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
| hsa0522031 | Liver | HCC | Chronic myeloid leukemia | 55/4020 | 76/8465 | 8.67e-06 | 6.91e-05 | 3.84e-05 | 55 |
| hsa0522511 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| hsa0451051 | Liver | HCC | Focal adhesion | 125/4020 | 203/8465 | 3.12e-05 | 1.88e-04 | 1.04e-04 | 125 |
| hsa0510032 | Liver | HCC | Bacterial invasion of epithelial cells | 51/4020 | 77/8465 | 6.67e-04 | 2.72e-03 | 1.52e-03 | 51 |
| hsa0472211 | Liver | HCC | Neurotrophin signaling pathway | 74/4020 | 119/8465 | 8.27e-04 | 3.26e-03 | 1.81e-03 | 74 |
| hsa0401211 | Liver | HCC | ErbB signaling pathway | 54/4020 | 85/8465 | 2.02e-03 | 7.07e-03 | 3.93e-03 | 54 |
| hsa0521411 | Liver | HCC | Glioma | 47/4020 | 75/8465 | 5.67e-03 | 1.62e-02 | 9.02e-03 | 47 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SHC2 | SNV | Missense_Mutation | c.620N>A | p.Ala207Glu | p.A207E | P98077 | protein_coding | deleterious(0.02) | possibly_damaging(0.474) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SHC2 | SNV | Missense_Mutation | c.816N>G | p.Ile272Met | p.I272M | P98077 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SHC2 | SNV | Missense_Mutation | novel | c.1636N>A | p.Val546Met | p.V546M | P98077 | protein_coding | tolerated(0.31) | benign(0.174) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SHC2 | SNV | Missense_Mutation | rs746427249 | c.1360N>A | p.Val454Met | p.V454M | P98077 | protein_coding | tolerated(0.21) | benign(0.011) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SHC2 | SNV | Missense_Mutation | rs200040363 | c.766G>A | p.Gly256Arg | p.G256R | P98077 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| SHC2 | SNV | Missense_Mutation | rs773645712 | c.1549G>A | p.Gly517Arg | p.G517R | P98077 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SHC2 | SNV | Missense_Mutation | novel | c.632G>A | p.Gly211Asp | p.G211D | P98077 | protein_coding | deleterious(0) | possibly_damaging(0.881) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SHC2 | SNV | Missense_Mutation | c.716N>A | p.Arg239His | p.R239H | P98077 | protein_coding | deleterious(0.01) | benign(0.189) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SHC2 | SNV | Missense_Mutation | rs746427249 | c.1360N>A | p.Val454Met | p.V454M | P98077 | protein_coding | tolerated(0.21) | benign(0.011) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SHC2 | SNV | Missense_Mutation | rs528045997 | c.1040N>T | p.Pro347Leu | p.P347L | P98077 | protein_coding | deleterious(0.02) | possibly_damaging(0.648) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |